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N E U R O S C I E N C E
Newly developed reversible MAO-B inhibitor 
circumvents the shortcomings of irreversible inhibitors 
in Alzheimer’s disease
Jong-Hyun Park1*, Yeon Ha Ju2,3,4*, Ji Won Choi1, Hyo Jung Song1, Bo Ko Jang1, Junsung Woo2,4, 
Heejung Chun4, Hyeon Jeong Kim1,5, Su Jeong Shin1,5, Oleg Yarishkin2, Seonmi Jo2, Mijeong Park6, 
Seul Ki Yeon1,5, Siwon Kim1,3, Jeongyeon Kim2, Min-Ho Nam2,4, Ashwini M. Londhe1,3, Jina Kim7, 
Sung Jin Cho7, Suengmok Cho8, Changho Lee8, Sung Yeoun Hwang9, Sang Wook Kim9,  
Soo-Jin Oh1,4, Jeiwon Cho6, Ae Nim Pae1,3, C. Justin Lee2,3,4,10†, Ki Duk Park1,3,11†
Monoamine oxidase–B (MAO-B) has recently emerged as a potential therapeutic target for Alzheimer’s disease 
(AD) because of its association with aberrant -aminobutyric acid (GABA) production in reactive astrocytes. Al-
though short-term treatment with irreversible MAO-B inhibitors, such as selegiline, improves cognitive deficits in AD 
patients, long-term treatments have shown disappointing results. We show that prolonged treatment with sele-
giline fails to reduce aberrant astrocytic GABA levels and rescue memory impairment in APP/PS1 mice, an animal 
model of AD, because of increased activity in compensatory genes for a GABA-synthesizing enzyme, diamine oxidase 
(DAO). We have developed a potent, highly selective, and reversible MAO-B inhibitor, KDS2010 (IC50 = 7.6 nM; 
12,500-fold selectivity over MAO-A), which overcomes the disadvantages of the irreversible MAO-B inhibitor. Long-
term treatment with KDS2010 does not induce compensatory mechanisms, thereby significantly attenuating in-
creased astrocytic GABA levels and astrogliosis, enhancing synaptic transmission, and rescuing learning and 
memory impairments in APP/PS1 mice.
INTRODUCTION
Alzheimer’s disease (AD) is characterized by significant, persistent, 
and progressive memory loss, usually accompanied by cognitive 
impairments and personality changes (1, 2). The histopathological 
hallmarks of AD consist of neurofibrillary tangles, caused by abnor-
mally phosphorylated tau, and amyloid plaques (3, 4). Thus far, the 
most widely accepted hypothesis for AD pathogenesis has focused 
on the gradual accumulation of amyloid beta (A) (5, 6). The dis-
ruption of this cascade has been the major strategy for drug devel-
opment (7). About half of the drugs in the AD pipeline target A (8), 
and their therapeutic mechanisms include the modulation of A pro-
duction and clearance of A by immunotherapies (9, 10). However, the 
repeated failures of A antibodies and -amyloid secretase 1 inhibi-
tors in clinical trials for AD call for a paradigm shift in the current 
hypothesis for the etiology of this debilitating disease (11–13).
The finding that aberrant levels of -aminobutyric acid (GABA), 
synthesized by monoamine oxidase–B (MAO-B) in reactive astro-
cytes, causes memory impairments in animal models of AD has sug-
gested the potential of an alternate, A-independent strategy for AD 
treatment (14, 15). The released astrocytic GABA strongly inhibits syn-
aptic transmission and diminishes the spike probability, leading to 
an impairment in synaptic plasticity and memory function (14). Sup-
pressing GABA production from reactive astrocytes by inhibiting MAO-B 
with selegiline, the most broadly used irreversible MAO-B inhibitor, 
fully restores the impaired spike probability, synaptic plasticity, 
and learning and memory function in the AD model mice, even in 
the presence of A (14). This concept introduces MAO-B as a po-
tential therapeutic target for treating memory impairments in AD.
Several clinical studies have reported that short-term treatment 
with selegiline improves cognitive deficits in patients with moder-
ate AD (16–18), suggesting that selegiline may delay functional de-
terioration and institutionalization of patients with AD. However, 
the outcomes of long-term treatments have been disappointing. A 
meta-analysis of 14 identified clinical trials that involved the long-
term treatment with selegiline of patients with AD has reported no 
statistically significant differences in cognition between selegiline 
and placebo groups (10, 19, 20). Therefore, there is a pressing need 
to investigate the direct link between irreversible MAO-B inhibitors 
such as selegiline and their diminishing effects in long-term treat-
ment. In the previous study, we observed that prolonged treatment 
with selegiline for 30 days failed to significantly reverse spatial 
memory impairments in the Morris water maze test in APPswe/
PS1dE9 (APP/PS1) mice (14) and suggested that the short-lived ac-
tion of selegiline was caused by compensatory mechanisms due to 
the irreversibility of its action (14).
In this study, we investigated the molecular mechanism that un-
derlies the diminishing effect of long-term selegiline treatment in 
the APP/PS1 mouse model. To overcome the shortcomings of irre-
versible inhibitors, we have developed a new, potent, selective, and 
reversible MAO-B inhibitor.
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RESULTS
The diminishing effect of long-term selegiline treatment
To corroborate the diminishing effects of selegiline after long-term 
treatment, we orally administrated selegiline (10 mg/kg per day) for 
a 4-week period in APP/PS1 mice and monitored the effects on hy-
pertrophied astrocytes and the level of GABA to compare with those 
of short-term treatment for a 3-day period. At this dose (10 mg/kg 
per day, orally), selegiline has been shown to specifically inhibit 
MAO-B activity in the brain (21). Consistent with our previous re-
port (14), we found that aberrant amounts of GABA accumulated in 
glial fibrillary acidic protein (GFAP)–positive reactive astrocytes in 
the molecular layer of the dentate gyrus (DG) in 10- to 12-month-old 
APP/PS1 mice. The aberrant GABA level in APP/PS1 mice was sig-
nificantly reduced to the level of GABA observed in wild-type (WT) 
mice after 3 days of selegiline treatment (Fig. 1, A and B). In marked 
contrast, the 4-week selegiline treatment resulted in the complete 
return of the aberrant level of GABA to untreated APP/PS1 levels 
(Fig. 1, A and B). Sholl analysis of individual GFAP-positive astro-
cytes revealed a significant but incomplete recovery in the complexity 
of astrocyte branching in both the 3-day and 4-week selegiline-treated 
groups (Fig. 1, C to E), indicating that selegiline only partially re-
duces the reactivity of astrocytes in diseased brains. The 1-week sele-
giline treatment was previously shown to be effective in rescuing 
memory impairments in the passive avoidance test in APP/PS1 mice 
(14). We found a similar full recovery with 3-day selegiline treatment 
(Fig. 1F). However, selegiline treatment for 4 weeks resulted in a 
diminished recovery of memory impairment (Fig. 1F). These results 
corroborate previous clinical reports on the diminishing effects of 
selegiline in long-term treatment.
KDS2010 is a new, potent, selective, and reversible MAO-B 
inhibitor with excellent ADME/Tox profiles
Developing a new drug for central nervous system (CNS) diseases 
has been particularly challenging with many obstacles to overcome, 
such as pharmacokinetics (PK) and blood-brain barrier (BBB) per-
meability, molecular target specificity in the CNS, and CNS safety. 
We aimed to identify a new MAO-B inhibitor that can act as a CNS 
drug and replace selegiline. We hypothesized that functionalized 
amino acids (FAAs) containing a biphenyl moiety would fulfill the 
requirements of a CNS drug. We designed and synthesized -amino 
amide derivatives containing a biphenyl moiety with various func-
tional groups on the phenyl ring B (Fig. 2A and fig. S1). We first 
introduced various electron-withdrawing groups on phenyl  ring B and 
observed an electron-withdrawing effect of the aryl substituent (X) 
on MAO-B inhibition with an increasing order of potency (X: CF3 > 
OCF3 > Cl > F > H). We then systematically placed electron-withdrawing 
groups at the ortho-, meta-, and para-position and found that the para- 
position (KDS2010) showed the highest potency among the derivatives 
(Fig. 2B, fig. S2, and table S1). KDS2010 exhibited higher potency 
[the half maximal inhibitory concentration (IC50) = 7.6 nM] and 
much greater selectivity for MAO-A (12,500-fold selectivity) than 
the irreversible inhibitor, selegiline (Fig. 2, C and D). Furthermore, 
KDS2010, which is the (S)-stereoisomer, showed a marked enantio-
mer selectivity (eightfold selectivity) over the (R)-isomer (Fig. 2D). 
Last, we confirmed reversibility of KDS2010 on MAO-B enzyme 
activity in a wash-and- recover experiment, as previously described 
(22). We observed that KDS2010 caused an over 80% recovery of 
enzyme activity, whereas almost no recovery was observed for sele-
giline (Fig. 2E and Supplementary Results).
We subsequently evaluated the drug-like properties of KDS2010 
through in vitro and in vivo absorption, distribution, metabolism, 
excretion, and toxicity (ADME/Tox) studies. KDS2010 showed low 
cytochrome P450 inhibitory activity (IC50 > 10 M for five isotypes), 
low hERG (human ether-à-go-go-related gene) inhibitory activity 
(IC50 > 50 M), and excellent stability in both the liver microsome 
(92% remaining) and plasma (98% remaining) (table S2 and Supple-
mentary Results). KDS2010 has an excellent pharmacokinetic profile 
with high bioavailability (>100%) and BBB permeability [brain-to-
plasma total drug concentration ratio: 9.2, comparison at 2 hours after 
oral administration (10 mg/kg)] (table S3 and Supplementary Re-
sults). Furthermore, KDS2010 was confirmed to be safe in vivo with 
no significant toxicity after oral administration of both a single dose 
of 1000 mg/kg and consecutive doses of 200 mg/kg per day for 14 days 
(table S2 and Supplementary Results). We also examined the off- 
target selectivity of KDS2010 with 87 primary molecular targets 
[G protein–coupled receptors (GPCRs), kinases, non- kinase en-
zymes, nuclear receptors, transporters, and various ion channels] and 
97 kinases (KINOMEscan). We observed an outstanding off-target 
selectivity at 1 M KDS2010 (no other target causing >40% inhibi-
tion) (Fig. 2F, fig. S3, and tables S4 and S5).
To understand the molecular interaction of KDS2010 with MAO-B, 
we performed an experiment to investigate the substrate-dependent 
kinetics of KDS2010 and to investigate the binding modes of KDS2010 
using the x-ray crystal structure of MAO-B bound with selegiline 
[Protein Data Bank (PDB) code: 2BYB] (23). We found that KDS2010 
was a competitive inhibitor (fig. S4 and Supplementary Results), tar-
geting the same binding cavity as selegiline, but its interaction with 
critical residues in the MAO-B binding cavity was more compact 
and reversible (Fig. 2G, fig. S5, and Supplementary Results). How-
ever, unlike selegiline, which formed a covalent bond with the co-
factor flavin adenine dinucleotide (FAD), it is possible that the amide 
tail of KDS2010 does not overlap with the FAD cofactor according 
to molecular modeling results. Together, we identified KDS2010 as a 
next-generation drug candidate with excellent drug-like properties 
and superior pharmacological profiles for the treatment of AD.
Compensatory metabolic pathways during long-term 
selegiline treatment
We investigated how the aberrant GABA levels are recovered after 
prolonged treatment with selegiline (Fig. 1A). We measured the 
mRNA expression level of each enzyme in the metabolic pathway 
leading to GABA synthesis (Fig. 3A) from cultured astrocytes after 
treatment with selegiline (100 nM) in the presence of putrescine for 
2 weeks (Fig. 3B). We found that the basal levels of diamine oxidase 
(DAO) mRNA in vehicle-treated astrocytes were lower than those 
of MAOB, GAD65, and GAD67 (Fig. 3C). The relative mRNA ex-
pression level of DAO was significantly higher in astrocytes treated 
with selegiline for 2 weeks than in vehicle-treated control astrocytes 
(Fig. 3D). The protein level of DAO was significantly higher in APP/
PS1 mice that underwent 4 weeks of selegiline treatment than in APP/
PS1 mice that underwent 4 weeks of KDS2010 treatment (Fig. 3, E 
and F). These findings suggest that prolonged treatment with sele-
giline reverts the GABA level via compensatory mechanisms involv-
ing enhanced GABA production by increased levels of DAO (24, 25). 
In contrast to selegiline, KDS2010-treated astrocytes did not show any 
sign of compensatory mechanisms. To determine whether DAO 
is involved in the tonic GABA increase when MAO-B enzyme activ-
ity is completely blocked, we performed whole-cell voltage-clamp 
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recordings from dentate granule cells in the hippocampus. We found 
that long-term treatment with selegiline significantly reverted aber-
rant tonic GABA currents in APP/PS1 mice (Fig. 3, G and H). The 
reverted aberrant tonic GABA currents after long-term selegiline 
treatment were completely blocked by incubation with the DAO 
inhibitor aminoguanidine (AG) for 2 hours. These results indicate 
that DAO is the main compensatory GABA-synthesizing enzyme in 
long-term selegiline treatment. In contrast, long-term treatment with 
KDS2010 persistently blocked the aberrant tonic GABA current in 
APP/PS1 mice (Fig. 3, G and H).
KDS2010 is effective in both short-term and  
long-term treatments
We subsequently found that treatment with KDS2010 for 3 days 
significantly ameliorated memory impairments in APP/PS1 mice 
(10 mg/kg per day) (fig. S6). To determine whether long-term treatment 
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Fig. 1. The diminishing effect of long-term selegiline treatment. (A) Immunostaining for GFAP, GABA, and DAPI (4′,6-diamidino-2-phenylindole) after oral administra-
tion of selegiline (10 mg/kg for 3 days or 4 weeks) in APP/PS1 mice (n = 4 for each group; both male and female mice aged 8 to 11 months were used). Inset: Magnified 
images. (B) Mean intensity of GABA in GFAP-positive areas. ****P < 0.0001, Kruskal-Wallis test with Dunnett’s multiple comparisons test. (C) Representative traced astro-
cytes from images such as those shown in (A) were superimposed over concentric circles for Sholl analysis. (D) Quantification of the total number of intercepts in a single 
astrocyte. **P < 0.01 and ****P < 0.0001, one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test. (E) Quantification of the ramification index of 
traced astrocytes. ****P < 0.0001, Kruskal-Wallis test with Dunnett’s multiple comparisons test. (F) Passive avoidance test results of WT and APP/PS1 mice, which either 
received or did not receive selegiline orally (10 mg/kg for either 3 days or 4 weeks). Left: Experimental protocol for the passive avoidance test. Right: Latency to enter the 
dark chamber during the passive avoidance test. *P < 0.05, Kruskal-Wallis test with Dunnett’s multiple comparisons test. AU, arbitary unit; APP., APP/PS1 mice; Sele., selegiline; 
3D, 3-day treatment; 4W, 4-week treatment. n refers to the number of cells (A and C) or mice (D) analyzed. n.s., not significant. Data are presented as means ± SEM. Bar 
graphs showing data distribution are presented in fig. S10.
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with KDS2010 suppresses GABA production in APP/PS1 mice, we 
orally administrated KDS2010 (10 mg/kg per day) for 4 weeks. We 
found that the immunoreactivity for GABA was significantly lower 
in GFAP-positive astrocytes of KDS2010-treated APP/PS1 mice than 
in water-treated control mice, and GFAP intensity was significantly 
reduced by KDS2010 treatment (Fig. 4, A and B). To evaluate the 
morphological features of astrogliosis, we performed Sholl analysis 
on GFAP-positive astrocytes. In KDS2010-treated APP/PS1 mice, the 
number of intercepts and ramifications in astrocytes were similar to 
those of astrocytes in WT mice (Fig. 4C). To examine the in vivo 
effect of KDS2010 on learning and memory, we performed passive 
avoidance tests after long-term treatment with KDS2010. Unlike 
selegiline, 4-week treatment with KDS2010 fully ameliorated the 
memory impairments in APP/PS1 mice (Fig. 4, D and E). In addition, 
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2-week treatment with KDS2010 ameliorated the memory impair-
ments (fig. S7, A and B) and suppressed aberrant tonic GABA 
currents (fig. S7, C and D) in a dose-dependent manner. We also con-
firmed the consequence of tonic inhibition on synaptically elicited 
action potential firing. We performed whole-cell current-clamp re-
cordings and measured the spike probability in DG granule neurons, 
as previously described (14). Consistent with a previous report, the 
spike probability was significantly lower in APP/PS1 mice than in 
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WT mice and was not recovered following selegiline treatment for 
either 2 or 4 weeks (Fig. 4, F and G). In contrast, we found that 
KDS2010 fully rescued the spike probability after treatment for 
2 and 4 weeks (Fig. 4, F and G). These results confirm the strong 
inverse correlation between tonic GABA currents and spike proba-
bility. In the case of high tonic GABA currents (APP/PS1, 4-week 
selegiline-treated APP/PS1; Fig. 3G), the spike probability was low, 
whereas in the case of low tonic GABA currents (WT, 4-week 
KDS2010-treated APP/PS1; Fig. 3G), the spike probability was 
high. Together, these results indicate that KDS2010 suppresses as-
trogliosis and aberrant GABA production and restores the spike 
probability.
KDS2010 restores spatial learning and memory in the Morris 
water maze test
We used the Morris water maze test to assess hippocampus-dependent 
spatial learning and memory in the treated mice (Fig. 5). As previ-
ously reported (14), APP/PS1 mice learned slower than WT mice. 
In the previous study, we observed that selegiline treatment only par-
tially ameliorated the learning and memory deficits in the Morris 
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water maze test (14), which was attributed to the fact that selegiline 
loses its efficacy when administered over long periods of time (14). 
First, we performed the Morris water maze test in APP/PS1 mice treated 
with KDS2010 for 28 days. In contrast to selegiline (14), after treat-
ment with KDS2010 for 28 days, spatial learning and memory signifi-
cantly improved during the acquisition test in APP/PS1 mice without 
affecting swimming speed (fig. S8, A to C). We also observed that there 
was no significant difference in escape latency and swimming speed 
between WT mice treated with KDS2010 and WT mice that were not 
treated with KDS2010 (fig. S8, B and C). We performed an additional 
Morris water maze test in APP/PS1 mice treated with KDS2010 for 
37 days (Fig. 5A). We confirmed that spatial learning and memory 
significantly improved in the acquisition test after treatment with 
KDS2010 for 37 days without affecting swimming speed (Fig. 5B and 
fig. S8D). The results of the probe test, which reflect the memory reten-
tion of the target location, also showed that the treatment of APP/PS1 
mice with KDS2010 significantly restored spatial memory (Fig. 5C). 
Reversal learning and memory was also fully restored by treatment 
with KDS2010 for 37 days (Fig. 5D). Together, KDS2010 effectively 
ameliorated the memory impairments in APP/PS1 mice, regardless of 
whether they were treated with KDS2010 for 28 days or 37 days.
DISCUSSION
In this study, we have demonstrated the potential mechanisms that 
underlie the compensatory up-regulation of alternative astrocytic 
GABA synthetic enzyme pathways following chronic treatment with 
an irreversible MAO-B inhibitor but not chronic treatment with a 
reversible MAO-B inhibitor (fig. S9). In summary, we have delin-
eated that the shortcomings of selegiline is due to a turning-on of 
the GABA-synthesizing enzyme DAO, resulting in a relapse of the 
aberrant GABA accumulation in reactive astrocytes. In contrast, the 
newly developed KDS2010 circumvents the issues of selegiline by sig-
nificantly attenuating increased astrocytic GABA levels and astro-
gliosis, enhancing synaptic transmission, and rescuing learning and 
memory impairments in APP/PS1 mice after both short-term and 
long-term oral treatments. KDS2010 retains its efficacy for long pe-
riods even in the presence of A.
The difference in the long-term efficacy between selegiline and 
KDS2010 can be explained by how reversible and irreversible inhibi-
tors differentially act on the MAO-B enzyme. Irreversible inhibitors 
covalently modify the MAO-B enzyme and eventually destroy the 
enzyme itself. In particular, since the turnover rate of the MAO-B 
enzyme in the brain is slow [the half-life for brain MAO-B protein 
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Fig. 5. KDS2010 significantly reversed spatial learning and memory impairments in the Morris water maze test. (A) The protocol for the Morris water maze test for 
APP/PS1 mice that either received or did not receive KDS2010 orally (10 mg/kg per day for 37 days; male mice 10 to 12 months of age). Acquisition tests were performed 
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is 40 days (26)], permanent damage to the MAO-B enzyme is ex-
pected to cause other enzymes to be recruited to compensate for the 
deficiency in MAO-B enzyme activity. We found that DAO is the 
major compensatory GABA-synthesizing enzyme because the DAO 
inhibitor fully blocked the relapsed tonic GABA currents under long-
term selegiline treatment. The increased DAO levels might lead to 
the conversion of putrescine to GABA (27), resulting in a relapse of 
GABA (Fig. 3A and fig S9). In contrast, reversible inhibitors occupy 
the active site of MAO-B and compete with substrates, resulting in 
an intact MAO-B enzyme. Thus, reversible inhibitors may not turn on 
the compensatory mechanisms because no MAO-B protein is dam-
aged or destroyed. Therefore, irreversible inhibitors in general should 
be used with caution because they destroy the target molecule, which 
can, in turn, trigger compensatory mechanisms. In our previous 
study (14), we also observed that the reversible inhibitor, safinamide, 
showed prolonged efficacy on spike probability. However, safinamide 
has other mechanisms of actions (28), including sodium channel in-
hibition, calcium channel inhibition, and glutamate release reduction, 
which may cause undesirable side effects during long-term therapy.
To overcome the drawbacks of existing irreversible and reversible 
MAO-B inhibitors, we have developed a variety of new reversible 
MAO-B inhibitors, which include benzothiazoles (29), chalcones 
(22), and FAAs. Among the FAAs, -amino amides containing a 
biphenyl moiety have exhibited the highest potency in both in vitro 
and in vivo model systems and have also shown better ADME/Tox pro-
files than other chemical scaffolds. The newly developed KDS2010 
meets all the prerequisites for preclinical CNS drug candidates with 
excellent PK and BBB permeability, molecular target specificity, and 
in vivo safety. According to the molecular modeling of KDS2010 
(Fig. 2G), two hydrogen bonds between the two amine protons of 
-amino amide and the oxygen atom of GLN206 in the MAO-B 
active site create a strong binding affinity, resulting in higher potency 
than that of other irreversible inhibitors. The biphenyl moiety of 
KDS2010, which has a flat structure and optimal lipophilicity, is 
most likely the key structure that is responsible for excellent BBB 
permeability. These conceptual breakthroughs in medicinal chemistry 
should be further investigated in the future.
Although the recent failure of the reversible MAO-B inhibitor 
sembragiline in a clinical trial involving patients with AD is dis-
couraging (30), our study offers plausible explanations for sembra-
giline’s failure. In the aforementioned clinical study, sembragiline 
was administered to patients with moderate to severe AD who had 
been taking either donepezil (5 to 10 mg daily) or rivastigmine (4.6 mg 
daily or 9.5 mg daily patch) for at least 6 months (30). The authors 
reported that, in their study, they did not observe any treatment effect 
because the study subjects were already receiving treatment during 
the study period and that the clinical efficacy of sembragiline may 
be noted in a monotherapy clinical trial (30). Another selective and 
reversible MAO-B inhibitor, lazabemide, has been shown to be 
clinically beneficial for the treatment of AD. It was tested as a mono-
therapy in patients with mild to moderate AD. Treatment with laz-
abemide resulted in a 20 to 40% reduction in the decline in cognitive 
function compared with a placebo during the phase 2 clinical trial. 
Although the phase 3 studies also provided consistent and statisti-
cally significant evidence of cognitive benefit relative to the placebo, 
the development of lazabemide was discontinued because of liver 
toxicity in 1999 (30). These results suggest that treatment with re-
versible MAO-B inhibitors would have been more effective in pa-
tients with mild to moderate AD without background treatment. 
Reviewing the potential success of reversible MAO-B inhibitors in 
clinical trials may be useful for developing an AD therapy.
Reactive astrocytes are the hallmark of astrogliosis and neuro-
inflammation, which are commonly observed not only in AD but 
also in other brain diseases, such as Parkinson’s disease, stroke, 
epilepsy, and traumatic brain injury (14). A recent report demon-
strates that an imbalance in the GABAergic system contributes to 
neuronal dysfunction in AD (31). In addition, MAO-B has been 
shown to be elevated in AD brain and regulate A production in 
neurons via -secretase (32). Therefore, these studies support our 
finding that MAO-B–driven aberrant GABA metabolism induces 
more severe AD pathologies, proposing MAO-B as the major tar-
get for relieving AD symptoms. We consistently observed that 
MAO-B inhibitors markedly reduce hypertrophy and astrogliosis 
in addition to astrocytic GABA. For example, selegiline signifi-
cantly reduced astrocytic reactivity in short-term treatment in AD 
model mice (14, 33, 34). KDS2010 almost completely reverted as-
trocytic reactivity to the WT level in both short-term and long-
term treatments (Fig. 4, A to C). Our study indicates that MAO-B 
is a key upstream molecular player of astrogliosis. Furthermore, 
these results suggest that KDS2010 is an effective pharmacological 
tool to prevent astrogliosis. Therefore, KDS2010 should be applied 
to other brain diseases in which reactive astrocytes are implicated 
and in which there is MAO-B–dependent aberrant GABA pro-
duction. These exciting possibilities should be examined in future 
investigations.
MATERIALS AND METHODS
Animals
All mice were kept in a temperature- and humidity-controlled envi-
ronment with a 12-hour light/12-hour dark cycle, and mice had free 
access to food and water. Handing and animal care was performed 
according to the directives of the Animal Care and Use Committee 
of the Institutional Animal Care and Use Committee of Korea Insti-
tute of Science and Technology (KIST) (Seoul, Korea). APP/PS1 
mice of B6C3 hybrid background originated from the Jackson Lab-
oratory (USA; stock number 004462) and were maintained as hemi-
zygotes by crossing transgenic mice to B6C3 F1 mice, which were 
derived from a cross between a C57BL/6 female and a C3H male. 
This hybrid strain is commonly used in the production of transgen-
ic mice. Both sexes of 8- to 13-month-old transgenic mice and WT 
littermates were used. In most behavioral experiments, mice were 
treated by oral administration with each concentration for sele-
giline or KDS2010 at 1 and 10 mg/kg per day. The amount of 
each drug (in mg) was calculated according to each mouse’s weight 
(in kg) and was dissolved in 100 l of water. Each oral administra-
tion was performed once per day. In the case of the Morris water 
maze experiment, 10 mg of KDS2010 was dissolved in 50 ml of wa-
ter. The mice were provided with water (control) and KDS2010 
solution ad libitum. Behavioral experiments were performed during 
the light phase of the light-dark cycle at the same time of each day. 
No statistical method was used to predetermine sample size. When 
using either sex, different litters, or ages of animals, animals were 
evenly allocated to each experimental group. All experiments were 
done with gender- and age-matched controls. Behavioral tests were 
conducted in a blind manner. The investigator was blinded to the 
group allocation of the genotype or treatment during the experi-
ment and when assessing all testing.
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Cell culture
Primary cortical astrocytes were prepared from 1-day postnatal 
C57BL/6 mice, as previously described (35). The cerebral cortex was 
dissected free of adherent meninges, minced, and dissociated into a 
single-cell suspension by trituration. Dissociated cells were plated 
onto plates coated with poly-d-lysine (0.1 mg/ml; Sigma). Cells were 
grown in Dulbecco’s modified Eagle’s medium (Corning) supple-
mented with glucose (4.5 g/liter), l-glutamine, sodium pyruvate, 10% 
heat-inactivated horse serum, 10% heat-inactivated fetal bovine 
serum, and penicillin-streptomycin (1000 U/ml). Cultures were 
maintained at 37°C in a humidified atmosphere containing 5% CO2. 
After 3 days, cells were vigorously washed with repeated pipetting 
using medium, and the medium was replaced to remove debris and 
other floating cell types.
Real-time polymerase chain reaction
Total RNA was isolated from mouse-cultured astrocytes using 
an RNA purification kit (GeneAll) according to the manufactur-
er’s instructions. Complementary DNA (cDNA) was synthesized 
from 1-g total RNA, and reverse transcription was performed 
using a SuperScript cDNA synthesis kit (Invitrogen) according 
to the manufacturer’s instructions. Real-time polymerase chain 
reaction was performed using a TaqMan gene expression assay 
(Invitrogen). Primer sets for MAOB, DAO, GAD65, and GAD67 
were purchased from Cosmogenetech. GAPDH was used as a house-
keeping gene. Primer sequence information is listed in table S6. The 
delta-delta Ct method was used to calculate fold changes in gene 
expression (36).
Slice immunostaining for confocal microscopy
For tissue fixation, mice were deeply anesthetized with 2% avertin 
(20 l/g, intraperitoneally) and perfused transcardially with 10 ml 
of heparinized normal saline, followed by ice-cold 4% paraformal-
dehyde with 0.5% glutaraldehyde solution. Excised brains were 
postfixed overnight in 4% paraformaldehyde and 0.5% glutaralde-
hyde at 0.9% saline and immersed in 30% sucrose for 48 hours for 
cryoprotection. After fixation, brains were mounted into an OCT 
(optimal cutting temperature compound) embedding solution and 
frozen at −20° to −80°C. Coronal hippocampal sections were cut at 
30 m in a cryostat and floated in phosphate- buffered saline (PBS). 
Sections were processed with three additional washes in PBS, incu-
bated for 1 hour in a blocking solution (0.3% Triton X-100  and 4% 
normal serum in 0.1 M PBS), and then immunostained with a mix-
ture of primary antibodies in a blocking solution at 4°C on a shaker 
overnight. After washing in PBS three times, sections were incubated 
with corresponding fluorescent secondary antibodies for 2 hours 
and then washed with PBS three times. If needed, then 4′,6- 
 diamidino-2-phenylindole (DAPI) staining was done by the addi-
tion of DAPI solution (1:1000; Pierce) during the second washing 
step. Last, sections were mounted with fluorescent mounting medi-
um (Dako) and dried. A series of fluorescent images were obtained 
with a FV1000 Olympus or an A1 Nikon confocal microscope, and 
30-m Z stack images in 2-m steps were processed for further 
analysis using FLUOVIEW (Olympus) or NIS-Elements (Nikon) 
software and ImageJ (National Institutes of Health) program. 
Any alterations in brightness or contrast were equally applied to 
the entire image set. Specificity of primary antibody and immuno-
reaction was confirmed by omitting primary antibodies or chang-
ing fluorescent probes of the secondary antibodies.
Antibodies
The primary antibodies used for immunostaining were as follows: 
chicken anti-GFAP (1:500; Millipore, ab5541), guinea pig anti-GABA 
(1:1000; Millipore, ab175), and rabbit anti-ABP1 (amiloride binding 
protein 1) (DAO) (1:500; Aviva Systems Biology, ARP41908_P050). 
Fluorescent secondary antibodies were purchased from Invitrogen or 
Jackson ImmunoResearch and used in 1:200 dilutions.
Tonic GABA recording
Brain slices were prepared from mice transgenic mice and WT litter-
mates aged around 8  to 13 months old. Mice were deeply anesthetized 
with 2-bromo-2-chloro-1,1,1-trifluoroethane. After anesthetization, 
the brain was quickly excised from the skull and submerged in ice-cold 
cutting solution that contained 250 mM sucrose, 26 mM NaHCO3, 
10 mM d-(+)-glucose, 4 mM MgCl2, 3 mM myo-inositol, 2.5 mM 
KCl, 2 mM sodium pyruvate, 1.25 mM NaH2PO4, 0.5 mM ascorbic 
acid, 0.1 mM CaCl2, and 1 mM kynurenic acid (pH 7.4). All the 
solutions were gassed with 95% O2 and 5% CO2. Hippocampal slices 
were obtained by vibrating microtome (Leica VT1000S), and 300-m-
thick coronal hippocampal slices were maintained at room tempera-
ture in a submerged chamber with extracellular artificial cerebrospinal 
fluid (ACSF) solution [126 mM NaCl, 24 mM NaHCO3, 1 mM 
NaH2PO4, 2.5 mM KCl, 2.5 mM CaCl2, 2 mM MgCl2, and 10 mM 
d-(+)-glucose (pH 7.4)]. Slices were incubated at room temperature 
for at least 1 hour before recording with gas bubbling. Slices were 
transferred to a recording chamber that was continuously perfused 
with ACSF solution (flow rate, 2 ml/min). The slice chamber was 
mounted on the stage of an upright Olympus microscope and 
viewed with a 60× water immersion objective (0.90 numerical aper-
ture) with infrared differential interference contrast optics. Cellular 
morphology was visualized by a charge-coupled device camera and 
Imaging Workbench software (INDEC BioSystems). Whole-cell re-
cordings were made from granule cell somata located in the DG. 
The holding potential was −70 mV. Pipette resistance was typically 
6 to 8 megaohms and filled with internal solution [135 mM CsCl, 
4 mM NaCl, 0.5 mM CaCl2, 10 mM Hepes, 5 mM EGTA, 2 mM 
Mg–adenosine triphosphate, 0.5 mM Na2–guanosine triphosphate, 
and 10 mM QX-314, pH adjusted to 7.2 with CsOH (osmolarity, 
278 to 285 mOsm)] (14). Baseline current was stabilized with d-AP5 
(50 M) and 6-cyano-7-nitroquinoxaline-2,3-dione (20 M) before 
measuring tonic current. Electrical signals were digitized and sam-
pled at 50-s intervals with Digidata 1440 A and a MultiClamp 
700B amplifier (Molecular Devices) using pCLAMP10.2 software. 
Data were filtered at 2 kHz. The amplitude of tonic GABA currents 
was measured by the baseline shift after bicuculline (100 M) ad-
ministration using the Clampfit program. Tonic current was mea-
sured from the baseline to bicuculline-treated current. Frequency 
and amplitude of spontaneous inhibitory postsynaptic currents 
before bicuculline administration were detected and measured by 
MiniAnalysis (Synaptosoft).
Evoked spike probability
Evoked spike probability recordings were made from horizontal 
brain slices with a thickness of 300 m, as described above. Synapti-
cally evoked spikes were triggered by a tungsten bipolar electrode 
placed in the outer half of the middle third dentate molecular layer. 
Stimulus intensity was set by 0.1-Hz stimulation of lateral perforant 
path fibers (100-s duration; 100- to 1000-mA intensity) via a con-
stant current isolation unit. The evoked EPSPs (excitatory postsynaptic 
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potentials) were recorded using glass pipette electrodes (6 to 8 MW), 
filled with intracellular solution containing 120 mM potassium 
gluconate, 10 mM KCl, 1 mM MgCl2, 0.5 mM EGTA, 40 mM Hepes 
(pH 7.2). Spiking probability was calculated as the ratio of the number 
of successful (spike-generating) stimulations to the total number of 
stimulations. Whole-cell patch-clamp recordings, using a Multi-
clamp7 amplifier (Molecular Devices), were performed from DG 
granule cells, visually identified with infrared video microscopy and 
differential interference contrast optics. Data were collected with a 
MultiClamp 700B amplifier (Molecular Devices) using Clampex10 
acquisition software (Molecular Devices) and digitized with Digidata 
1322A (Molecular Devices). Raw data were low pass–filtered at 
4 kHz and collected for offline analysis at a sampling rate of 10 kHz 
using pClamp10.2 software.
MAO-A and MAO-B enzyme assay
Evaluation of the IC50 of compound for MAO enzyme activity was 
based on previously described methods (22). Human recombinant 
MAO-A (hMAO-A) and MAO-B (hMAO-B) enzymes prepared 
from insect cells were obtained from Sigma-Aldrich. hMAO-A and 
MAO-B enzymes (for MAO-A, 6 l from 5.0 mg/ml solution; for 
MAO-B, 50 l from 5.0 mg/ml solution) were diluted in aqueous 50 mM 
phosphate buffer (10 ml, pH 7.4). The enzyme solution (98 l; final 
protein amounts: ~0.3 g of protein per well for MAO-A and ~2.5 g 
of protein per well for MAO-B) was treated with test compound 
in dimethyl sulfoxide (2 l; final concentration, 0.1 nM to 10 M) and 
then incubated for 15 min at room temperature. The resulting solu-
tion (100 l) was treated with an assay solution (100 l), which is the 
mixed solution of 20 mM Amplex Red reagent (200 l; final concen-
tration, 0.2 mM), 100 mM substrate (200 l; MAO-A: p-tyramine, 
MAO-B: benzylamine, final concentration, 1 mM), and horseradish 
peroxidase (200 U/ml) (100 l; final concentration, 1 U/ml) in 
aqueous 50 mM phosphate buffer (9.5 ml, pH 7.4). After 20 min of 
incubation, the released hydrogen peroxide (H2O2) and the subse-
quent production of resorufin were quantified using a microplate 
fluorescence reader (SpectraMax i3 reader, Molecular Devices) with 
an excitation at 545 nm and an emission at 590 nm.
Reversibility test
The reversibility of MAO-B inhibition was measured using the 
previous method (22). Briefly, the recombinant hMAO-B enzymes 
(50 l from 5.0 mg/ml solution) were diluted in aqueous 50 mM 
phosphate buffer (2 ml, pH 7.4). The enzyme solution (441 l) was 
incubated with the 0.05 mM MAO-B inhibitor (9 l; final concentra-
tion, 2 M) at room temperature (30 min) and then divided into two 
aliquots (200 l) of reaction enzyme solution. An aliquot (200 l) 
was examined for hMAO-B activity using the method described above. 
Another aliquot (200 l) was used for the washout experiment. For 
washout experiment, the aliquot was placed in an Amicon Ultra 
centrifugal filter (3 kDa) (Millipore) and centrifuged (14,000g) at 4°C 
(10 min). The enzyme retained in the membrane was resuspended 
in 50 mM phosphate buffer (1 ml) and centrifuged again (under 
same conditions described above) for three consecutive times. The 
resulting enzyme was resuspended in aqueous 50 mM phosphate 
buffer (200 l, pH 7.4), and the solution was used for determination 
of the remaining enzyme activity. Control experiments without test 
compounds were performed with the vehicles to define 100% hMAO- 
B activity. The corresponding values of percent (%) inhibition were 
separately determined before and after washout.
Molecular docking study
Ligands were sketched using ChemDraw Professional V15.0 pro-
gram. X-ray crystal structure of MAO-B bound with selective inhibitor 
selegiline (PDB code: 2BYB) with a 2.2-Å resolution was taken from the 
PDB. The protein and ligands were prepared using Protein Prepare 
Wizard and LigPrep module implement in Maestro (Schrödinger 
LLC, NY, USA), respectively. The protein was fixed by adding miss-
ing side chain and neutralized at pH 7.4. Water was removed with 
less than one hydrogen bond to non-waters, and only hydrogens 
were minimized with an OPLS_2005 force field. Ligands were pro-
tonated at neutral pH using Epik and energetically minimized with 
an OPLS_2005 force field. The docking study (37, 38) was performed 
using Glide with the standard precision scoring function. Figures 
were rendered with pymol program (www.pymol.org).
Off-target selectivity
To evaluate the activity of KDS2010 on off-targets, the SafetyScreen 87 
panel assay was performed at Eurofins Cerep-Panlabs (Taipei, Taiwan) 
using validated radio-ligand competition binding assays and enzymatic 
inhibition assays. Experimental conditions for each of these 87 assays 
are available at the Eurofins web page (www.eurofinspanlabs.com) 
(see also table S4). To eliminate the possibility of kinase off-target 
hits, a scanEDGE kinase assay panel was conducted in DiscoverX 
(CA, USA) using a binding reaction in combination with kinase, 
liganded affinity beads, and test compounds. Experimental condi-
tions for these 97 assays are available at the DiscoverX web page 
(www.discoverx.com) (see also table S5).
Passive avoidance test
Before the experiment, mice were handled daily for 7 days. Mice 
were placed in two-compartment (light and dark) shuttle chambers 
with a constant current shock generator (MED Associates). On the 
first experimental day, a mouse was put in the light chamber for the 
acquisition trial. After 60 s of exploration, the door separating 
the light and dark compartments was raised, allowing the mouse to 
freely enter the dark chamber. When the mouse entered a dark 
chamber with all four paws, the door immediately closed and an 
electric foot shock (0.5 mA, 2 s duration) was delivered through the 
floor grid. The mouse was then returned to the home cage, and the 
retention trial was carried out 24 hours after the acquisition trial. 
On the second experimental day, the mouse was placed into the 
light chamber again. After 60 s of exploration, the door was raised 
to allow the mouse to enter the dark chamber. The step-through 
latencies of entering the dark chamber before and after the electric 
shock were measured to a maximum of 600 s.
Morris water maze
Two separate water maze tests were performed using male APP/PS1 
mice (28-day treatment and 37-day treatment) (fig. S8 and Fig. 5). The 
water maze (1.2-m diameter) was filled with water (24° to 25°C) and 
made opaque by the addition of nontoxic white paint (WeatherTough 
Forte, Bristol Paints). The water maze was surrounded by a black 
circular curtain (placed 70 cm away) that held three salient visual 
cues. Before the water maze test, mice were handled for 7 days. Mice 
were released and randomly distributed across four quadrants of the 
water maze, and the mice were allowed a maximum of 60 s to find a 
hidden platform (10-cm diameter, 1 cm under the water surface). 
Mice were trained for 7 days (4 trials per day, 10-min intertrial in-
terval). On training day 8, mice were given a 60-s probe test (sans 
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the platform) to test their spatial memory. After the probe test, the 
hidden platform was placed on the opposite quadrant. Mice were 
trained an additional 3 days of reversal training. An automated track-
ing system (EthoVision, Noldus) was used to monitor the animal’s 
swimming pattern, speed, and the amount of time spent in each of 
the four quadrants.
Statistical analyses
For comparison of multiple groups, one-way analysis of variance 
(ANOVA) with Tukey’s multiple comparison test and Dunnett’s 
multiple comparison test were assessed using Prism software. P val-
ues less than 0.05 were considered significant. The significance level 
is displayed as asterisks (*P < 0.05, **P < 0.01, ***P < 0.001, and 
****P < 0.0001; n.s. not significant). For all comparisons, samples 
were not excluded from data except only for tonic GABA current 
recording; cells with holding currents over −100 pA were excluded, 
and experiments were stopped after 3 hours from the time of slic-
ing. No animal was excluded from analysis in behavioral experi-
ments. When using either sex, different litters, or ages of animals, 
animals were evenly allocated to each experimental group, and for 
slice immunostaining and electrophysiological experiments, we 
randomly conducted samples in each experimental group. Detailed 
results for ANOVA are described in table S6.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/3/eaav0316/DC1
Supplementary Results
Supplementary Materials and Methods
Fig. S1. General procedure for the preparation of KDS compounds.
Fig. S2. Structure-activity relationship of the synthesized compounds.
Fig. S3. The KINOMEscan screening results with 1000 nM KDS2010 for off-target selectivity.
Fig. S4. Mode of KDS2010 binding with MAO-B.
Fig. S5. Three-day and 2-day interactions of selegiline, KDS2010, and KDS0014 inside MAO-B.
Fig. S6. Acute treatment of KDS2010 (3 days) restored memory impairment in APP/PS1 mice.
Fig. S7. Passive avoidance test for learning and memory in APP/PS1 mice with 2-week 
KDS2010 treatment.
Fig. S8. KDS2010 significantly recovers spatial learning and memory in Morris water maze.
Fig. S9. Model diagrams of long-term treatment of AD with either irreversible or reversible 
MAO-B inhibitors.
Fig. S10. Data distribution of bar graphs.
Table S1. Inhibitory effects of the synthesized compounds against hMAO enzymes.
Table S2. In vitro and in vivo ADME/Tox profile of KDS2010.
Table S3. In vivo pharmacokinetic parameters of KDS2010.
Table S4. KDS2010 interactions with 87 primary molecular targets including GPCRs, kinases, 
non-kinase enzymes, nuclear receptors, transporters, and various ion channels.
Table S5. KDS2010 interactions with 97 kinase including TK, TKL, STE, CK1, AGC, CAMK, CMGC, 
ATYPICAL, LIPID, and Mutant form.
Table S6. Detailed information for statistical analysis.
Table S7. Primer sequences for each enzyme (F: forward primer and R: reverse primer).
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